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Abbreviations 
ABMR antibody-mediated rejection 
BPAR  biopsy-proven acute rejection 
CDC complement-dependent cytotoxicity 
CMV  cytomegalovirus 
DSA donor specific antibodies 
dnDSA  de novo donor specific antibodies 
HLA human leukocyte antigen 
IL-2RA interleukin 2 receptor antagonist 
IVIG intravenous immunoglobulin 
MMF  mycophenolate mofetil 
NK  natural killer 
PRA  panel reactive antibodies 
PTLD post-transplant lymphoproliferative disease 
rATG  rabbit antithymocyte globulin 
TCMR T-cell mediated rejection 
Tregs T-regulatory cells 
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Abstract 
The mode of action of rabbit antithymocyte globulin (rATG) includes preferential 
inhibition of pre-existing donor-reactive memory T-cell reconstitution and possibly 
apoptosis of plasma cells, the source of donor specific antibodies (DSA). In kidney 
transplant patients with low-strength preformed DSA, non-comparative data have shown 
a low incidence of antibody-mediated rejection (ABMR) and graft survival using rATG 
even without desensitization procedures. For high strengths of preformed DSA, rATG 
induction with more aggressive desensitization appears effective, with mixed results 
concerning the addition of B-cell specific agents. Regarding production of de novo DSA 
(dnDSA), interpretation of retrospective analyses is limited by selective use of rATG in 
higher-risk patients. Observational data in moderately sensitized kidney transplant 
patients suggest that the incidence of dnDSA and ABMR is significantly lower with rATG 
versus basiliximab. A randomized pilot study has suggested that addition of rituximab or 
bortezomib may not further inhibit dnDSA production in rATG-treated patients. Overall, 
rATG appears to inhibit DSA production, with a potential role in reducing the risk of 
ABMR in kidney transplant patients with high-strength preformed DSA, or lowering 
dnDSA in moderately sensitized patients. Randomized trials are awaited.  
Keywords:  rATG, rabbit antithymocyte globulin, Thymoglobulin, DSA, donor specific 
antibodies, antibody mediated rejection 
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Introduction 
The poor prognosis associated with anti-human leukocyte antigen (HLA) donor-specific 
antibodies (DSA) following kidney transplantation is well-established. Preformed class I 
and II DSA, in particular, confer a marked increase in the risk of antibody-mediated 
rejection (ABMR) [1-3] and reduced allograft survival [1, 2, 4, 5], even when the titer is 
below the threshold for a positive crossmatch, whereas preformed complement (C1q)-
fixing DSA shows a less convincing association with poor outcomes [6, 7]. Development 
of de novo DSA (dnDSA) after kidney transplantation also incurs a higher risk for acute 
rejection [8, 9], chronic ABMR [10] and graft survival [4, 10, 11]. Complement-binding 
dnDSAs show a particularly strong association with ABMR and graft failure, increasing 
the risk of graft loss by over four-fold [10]. Rates of acute T-cell mediated rejection 
(TCMR) and ABMR are both higher in kidney transplant patients who develop dnDSA 
compared to recipients with preformed DSA [12], and the combination of ‘mixed’ TCMR 
and ABMR is especially unfavorable. Of note, donor-specificity of HLA antibodies is 
highly important; HLA antibodies that are not donor-specific appear to be less relevant 
[1]. 
There is no conclusive evidence to confirm that any immunosuppressive regimen or 
agent prevents or delays DSA production. However, randomized clinical trials, 
undertaken before routine DSA monitoring was adopted, have pointed to a possible 
effect for rabbit antithymocyte globulin (rATG) induction. Randomized studies have 
shown rATG to be effective in preventing biopsy-proven acute rejection (BPAR), and 
specifically, steroid-resistant BPAR, in kidney transplant patients categorized as 
sensitized based on anti-HLA panel reactive antibody (PRA) status or other established 
risk factors [13–15]. An early trial of 89 patients with PRA in the range 5–100%, with or 
without positive complement-dependent cytotoxicity (CDC) B-cell crossmatch, showed 
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that compared to no induction, rATG induction significantly reduced BPAR and 
increased one-year graft survival and function, even at the highest levels of sensitization 
(PRA >80%) [15]. Rates of ABMR were not reported. More recently, a randomized trial 
comparing rATG induction versus the interleukin 2 receptor antagonist (IL-2RA) 
daclizumab in 227 HLA-sensitized kidney transplant patients (current PRA ≥30% and/or 
peak PRA ≥50%) receiving tacrolimus, mycophenolate mofetil (MMF) and steroids as 
maintenance therapy showed a significant reduction rate of BPAR and steroid-resistant 
BPAR in the rATG-treated cohort at one year [14]. There was no difference in the rate of 
ABMR (one case occurred in each treatment arm), but interestingly only two rATG 
patients were given intravenous immunoglobulin (IVIG) and/or plasmapheresis (with 
another given OKT3), while in the daclizumab arm  six patients were given IVIG, 
plasmapheresis or rituximab, and a further seven needed anti-rejection treatment with 
rATG. Brennan et al also reported a significant benefit for rATG versus IL-2RA induction 
in terms of BPAR and steroid-resistant rejection in another cohort of kidney transplant 
patients at increased risk for acute rejection or delayed graft function [13]. A systematic 
review with a meta-analysis has confirmed that when IL-2RA induction (basiliximab or 
daclizumab) is compared to ATG (16 randomized controlled trials, 2,211 participants), 
there is a benefit for ATG therapy over IL-2RA in terms of BPAR at one year, but at the 
cost of an increase in malignancy and cytomegalovirus (CMV) disease [16]. However, 
the meta-analysis included studies from the 1990s and early 2000s when ATG doses 
were markedly higher than at present, and also included several studies of equine ATG, 
so applicability to rATG induction with modern regimens is not certain. More recent 
registry analyses have shown mixed findings in terms of risk for post-transplant 
lymphoproliferative disease (PTLD) or malignancy, but again can be difficult to interpret 
since they were not necessarily specific to rATG [17–20]. In the TAILOR registry of 
living-donor kidney transplant recipients, 2,322 patients transplanted in 2003–2008 and 
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given a mean cumulative rATG dose of ~5.3mg/kg showed a PTLD incidence of 0.9% at 
five years, comparable with the kidney transplant population overall [20]. These data are 
a reminder that the overall intensity of immunosuppression should not be 
disproportionately increased, to avoid a heightened risk of malignancies and infections.  
While these trials do not provide direct evidence regarding an influence of rATG on pre-
existing DSA or the development of dnDSA, they do suggest that use of rATG induction 
merits further exploration to examine the balance of benefits and risks. The current data 
relating to rATG (Thymoglobulin) and anti-HLA DSA are discussed here.  
 
The mode of action for rATG: potential relevance to DSA production  
ABMR is a progressive process, diagnosed based on the presence of circulating DSA 
with specific histologic criteria (primarily microvascular inflammation and transplant 
glomerulopathy) and immunohistologic characteristics [21, 22].  
rATG interacts with a large range of antigens on immune and non-immune cell types, 
inducing apoptosis of B-cells, peripheral T-cells and natural killer (NK) cells, and 
modulates leukocyte/endothelium interactions [23–25]. Evidence from a murine model 
has shown that rATG targets pre-existing donor-reactive memory T-cells, suppressing 
their recovery more effectively than other components of the T-cell response [26]. In 
addition, the well-documented phenomenon of preferential reconstitution of T-regulatory 
cells (Tregs) after rATG treatment [27–29] may also be beneficial.  
rATG may also exert a direct effect, since it contains antibodies against several plasma 
cell antigens. In vitro studies by Zand et al have shown that rATG strongly induces 
apoptosis in terminally differentiated plasma cells (CD138+) at clinically relevant 
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concentrations (1–100ng/mL) via a complement-independent process [30] and may thus 
potentially inhibit production of DSA, although this has not been demonstrated in these 
studies. Other researchers, however, have observed no effect of rATG (or rituximab or 
IVIG) on plasma cell apoptosis in vitro [31] or in vivo after desensitization with rATG [32], 
although CD27+ memory B-cells appear to be depleted [32].  
Taken together, from the complex impact of rATG on blood cell constituents, especially 
on the plasma and Treg compartment, it could be hypothesized that rATG also affects 
DSA production post-transplant and the risk for ABMR. However, this remains to be 
evaluated.  
rATG in presensitized patients 
Anti-HLA antibodies have been detected in 10–24% of patients prior to kidney 
transplantation [33–35], with estimates influenced by the choice of techniques and the 
era of the study population.  Organ matching is challenging in broadly sensitized patients 
due to the high immunologic barrier. Even if transplantation is performed and 
crossmatches are negative, presensitization with DSA predicts poor graft survival [10, 34, 
36–38]. Survival is especially low when DSA persist [10] or increase [39] post-transplant, 
due to higher rates of ABMR [36, 39]. Known risk factors for presensitization against 
HLA antigens include prior blood transfusions [40, 41], pregnancy [40], and previous 
surgery including prior transplantation [42]. Infectious agents may also potentiate an 
anti-HLA response as a result of molecular mimicry [43].  
Desensitization protocols are complex, but the most widely used downregulation 
strategies are plasmapheresis and/or IVIG, frequently with intravenous administration of 
the chimeric monoclonal anti-CD20 antibody rituximab. There has also been recent 
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interest in the plasma cell-targeted protease inhibitor bortezomib and the anti-
complement antibody eculizumab [44]. These regimens have acceptable short-term graft 
survival, but rates of acute rejection and ABMR remain much higher than in non-
sensitized patients [45]. Encouragingly, however, a large cohort study of 211 live donor 
kidney recipients reported a significant survival benefit following desensitization versus 
remaining on dialysis [46].  
Numerous studies have reported outcomes using different preconditioning regimens and 
rATG induction, as discussed below. With no consensus regarding the optimal 
combination and doses of desensitizing techniques, these studies describe a wide range 
of populations and methodologies. No trial has compared outcomes following a 
preconditioning regimen with or without the use of rATG induction, limiting an accurate 
assessment of the specific contribution of rATG in any regimen.  
– Low-strength DSA 
The risk of ABMR increases with DSA strength at the time of transplantation [47]. 
Nevertheless, in candidates with low-strength DSA (i.e. DSA detectable only on more 
sensitive assays such as flow-cytometric crossmatch or single antigen flow beads), 
ABMR rates are still higher than in DSA-negative patients despite relatively weak 
sensitization. Without preconditioning, acute and chronic ABMR has been reported in 
33% and 42% of these patients [48], although graft survival rates are typically similar to 
patients with negative crossmatch [47]. No study has compared outcomes using rATG 
induction or no rATG induction in kidney transplant patients with low-strength DSA. Two 
centers have described the results of desensitization in a population of kidney transplant 
recipients with low-strength DSA who received rATG induction, with no control regimen 
[49, 50] (Table 1). Bächler and colleagues prospectively identified the presence of low-
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strength DSA by single antigen flow beads (‘virtual crossmatch’) in 37 candidates (all 
with negative T-cell and B-cell CDC crossmatch) who received IVIG prior to graft 
reperfusion and on days 1–4 (total dose 2g/kg), with rATG (using the Fresenius 
preparation, not Thymoglobulin®) 9mg/kg prior to reperfusion and 3mg/kg on days 1–4 
[49]. Maintenance immunosuppression comprised tacrolimus, MMF and steroids.  
Compared to a cohort of 67 historical controls, also with low-strength DSA but without 
additional treatment with IVIG or rATG (but with IL-2 receptor blockade in 48%), the rate 
of ABMR in clinically-indicated biopsies was markedly lower six months after 
transplantation in the IVIG/rATG treatment group (11% versus 46%, p=0.0002). In 
addition, the rate of TCMR in indication biopsies was also significantly lower in the 
IVIG/rATG-treated patients (0% versus 50%, p<0.0001). Subclinical TCMR on protocol 
biopsies at three and six months was also less frequent in the IVIG/rATG cohort (11–
18% versus 43–46%, p=0.008-0.03) [49]. The rate of subclinical ABMR did not differ 
between the groups. Akalin et al identified a subgroup of patients who were CDC 
crossmatch T-cell negative but B-cell positive, or flow cytometry crossmatch positive, 
and stratified them according to DSA strength on single antigen flow bead assay [57] 
(Table 1). In the 12 patients with ‘weak or moderate’ DSA strength, IVIG with rATG 
induction (1.5mg/kg/day for five days) and a regimen of tacrolimus, MMF and steroids 
prevented graft rejection entirely, although the absence of a control group means that 
strong conclusions cannot be drawn. In contrast, other small retrospective studies 
comparing patients with low-strength DSA versus a DSA-free control group have 
suggested that ABMR and graft survival rates are similar even in the absence of 
desensitization procedures when using rATG induction with tacrolimus, MMF and 
steroids [51, 52]. 
– High-strength DSA 
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Compared to patients with low-strength DSA, patients with high-strength DSA are 
at significantly greater risk of ABMR, as well as both early and late graft loss [38, 
47]. Stegall and colleagues used rATG induction in 61 patients with CDC T-cell 
positive crossmatch [55] (Table 1). The desensitization protocol evolved over the 
period of analysis, from (i) plasmapheresis with low-dose IVIG and rituximab (with 
splenectomy in the early cases), to (ii) high-dose IVIG switching to the earlier 
regimen for non-responders, then finally to (iii) plasmapheresis, low-dose IVIG and 
rituximab with pre-transplant rATG. rATG (1.5mg/kg/day) was given after 
plasmapheresis on the first five days of the preconditioning regimen with post-
transplant DSA monitoring and further intervention was given as required to 
maintain a low DSA strength [55]. The latter regimen, with rATG induction, 
achieved a lower rate of ABMR than the early rituximab-containing protocol (29% 
versus 37%), although follow-up times are not reported.  One study, by Vo et al, 
has compared rATG induction versus IL-2RA induction (daclizumab) in two 
sequential cohorts of CDC crossmatch-positive patients who received IVIG 
preconditioning [54]. In the earlier phase of this retrospective study, 58 patients 
received daclizumab; latterly, 39 patients were given rATG induction. The 
incidence of ABMR by two years was similar (daclizumab 21%, rATG 22%) [54]. 
Graft survival (84% and 90%, respectively) and patient survival (96% and 100%, 
respectively) were not significantly different (Table 1), but more daclizumab-
treated patients were crossmatch-negative by the time of transplant (48% versus 
25%, p<0.03), which is likely to have skewed the results [54]. Confirmatory trials 
are awaited. 
Other centers have reported their experience with rATG induction after use of various 
preconditioning protocols, allocated according to the risk level of transplant candidates 
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based on T-cell immunoglobulin titers, positive T-cell and/or B-cell crossmatch by CDC, 
flow cytometry, ELISA or single antigen flow bead assay [58–60]. Some reports have 
administered rATG in an unidentified proportion of patients [46, 60, 61], making it difficult 
to identify the contribution of rATG. One randomized trial in 40 kidney transplant patients 
has compared rATG alone (9mg/kg total dose) to rATG (6–7.5mg/kg) with rituximab or 
with bortezomib, or with both agents [62]. The study population, however, included 
patients if they had high cytotoxic PRA levels or prior allograft loss with more than one 
rejection, as well as patients with confirmed DSA by CDC or flow cytometry, and no 
more than 6/10 patients in each treatment group had a confirmed positive crossmatch or 
DSA. Nevertheless, it is interesting that an increase in preformed DSA occurred in no 
patients given rATG alone, but in up to 40% of patients in the other groups. However, 
rATG with rituximab entirely prevented ABMR, whereas one patient (10%) given rATG 
alone had ABMR and three patients (30%) given rATG and bortezomib had ABMR, one 
of whom lost their graft as a result [62]. Addition of B-cell specific agents to rATG 
induction may be effective, but these findings are inconclusive and trials exclusively in 
recipients with pre-existing DSA are lacking. Moreover, it should be noted that one 
retrospective study of 77 kidney transplant patients given rituximab for various reasons 
showed a significantly higher rate of death from infectious causes than a control group of 
patients without rituximab therapy [63]. 
Overall, rATG induction for presensitized kidney transplant patients, even with low-
strength DSA, appears to be an appropriate adjunct to the desensitization process. In 
patients with high strengths of pre-transplant DSA, the potential incremental benefit of 
rATG with additional preconditioning strategies remains unclear, and no firm conclusions 
can be drawn regarding the use of rATG in this setting.  
De novo DSA  
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Little is known about the dominant risk factors for dnDSA. Two proposed factors are 
poor HLA matching, particularly at the DQ locus [11, 64, 65], and non-adherence to the 
immunosuppressive regimen [66]. Younger patients (e.g. <50 years) are at increased 
risk [8, 67], possibly due to a more robust immunological response and greater non-
adherence. African American recipients may also be prone to develop dnDSA [64]. 
Recent studies have reported an incidence of 8–11% by the end of the first year after 
kidney transplantation [68, 69], rising as high as 25% in patients at high immunological 
risk [62]. Although theoretically use of rATG induction therapy to inhibit activity of both T-
cells and B-cells in the immediate post-transplant period would seem a rational strategy 
to reduce early dnDSA production in at-risk individuals [23], published data supporting 
this is particularly limited.  
rATG induction and dnDSA production 
Prospective data on the rate of dnDSA are available from a subpopulation analysis of 37 
kidney transplant patients taking part in a randomized trial assessing early corticosteroid 
withdrawal, all of whom received rATG induction with tacrolimus and MMF maintenance 
therapy [70]. All patients showed a negative CDC crossmatch at baseline. Annual follow-
up included mixed bead antigen testing, with single antigen flow bead testing in those 
who tested positive. By year 5, only one of the 37 patients (2.7%) had developed dnDSA, 
but this low rate may have reflected the study definition of dnDSA i.e. antibodies which 
developed after the first post-transplant year [70].  
Retrospective analyses [4, 8, 12] have described the baseline characteristics –- 
including the type of induction therapy – in kidney transplant patients who did or did not 
develop dnDSA during follow-up, but interpretation is hampered by bias in the use of 
rATG induction. Huang et al administered rATG pre-transplant in all high-risk patients 
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(defined as preformed DSA, African American recipients, retransplants, or PRA >20%) 
and used basiliximab, rATG or no induction in low-risk patients [12] (Table 2). The 
observation that there was no significant difference in rATG use in patients with or 
without dnDSA (Table 3) is largely unhelpful given the selective nature of rATG 
administration (Table 3). Similarly, Cooper et al observed an identical proportion of rATG 
use in a series of 244 patients who did or did not develop dnDSA by month 24 post-
transplant, but rATG was again used preferentially in recipients at higher immunologic 
risk [8]. Consistent with this, a retrospective analysis of 1,229 patients undergoing kidney 
transplant over an extended period (1972–2002) has reported the use of rATG to be 
higher in the subpopulation who developed dnDSA (Table 3) but the difference was lost 
on multivariate analysis, reflecting the selective use of rATG in patients at high risk (i.e. 
retransplant, PRA ≥15% or cold ischemia ≥36 hours) [4]. Kanter Berga et al undertook a 
cross-sectional analysis of dnDSA occurrence based on single antigen flow bead assay 
in 321 recipients of a kidney transplant at standard immunological risk, and observed the 
use of induction (either rATG or basiliximab) to be significantly lower in the patients who 
developed dnDSA versus those who remained non-sensitized or developed non-DSA 
HLA antibodies (22.2% versus 54.5% and 70%, p=0.02), but data were not provided 
separately for rATG and basiliximab [73].  
One recent retrospective analysis has reviewed the development of dnDSA in 196 non-
sensitized patients undergoing heart transplantation at a single center during 2006 to 
2013 [74]. rATG induction was given at a dose of 1.5 mg/kg for 3–5 days in 35 patients, 
with no induction in the remaining patients. Maintenance therapy comprised tacrolimus, 
MMF and steroids across the entire population. At one year, the proportion of patients 
with de novo HLA antibody production was significantly lower in the subgroup treated 
with rATG (11% versus 21% in patients without induction, p=0.043) but dnDSA was 
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similar (9% versus 12%, p=0.541). Imbalances between the two groups, and the 
relatively short follow-up time, may have influenced the results.  
- Comparisons with other induction regimens 
A recent observational analysis has compared the incidence of dnDSA in 114 
consecutive kidney transplant patients who received either rATG or basiliximab 
induction, both with tacrolimus, MMF and steroid maintenance therapy [71]. The patients 
were all moderately sensitized: inclusion criteria were negative crossmatch on flow 
cytometry but DSA-positive using single antigen flow bead testing (500 to 4,000 mean 
fluorescence intensity [MFI]). The desensitization protocol comprised plasmapheresis 
with IVIG, and rATG or basiliximab induction was given according to physician 
preference. As might be expected, the rATG group were at higher immunological risk, 
with significantly higher peak PRA (p=0.03), greater use of plasmapheresis/IVIG 
(p=0.0008) sessions, and more IVIG injections compared to the basiliximab-treated 
patients [71]. Despite this, after a follow-up of up to three years, rates of dnDSA and 
ABMR were both significantly lower in the rATG-treated cohort based on Kaplan-Meier 
analyses (Figure 1).  Interestingly, the benefit for rATG appeared relatively late – after 
month 12. The benefits of rATG were confirmed in a stepwise multivariate regression 
analysis, which showed a hazard ratio (HR) of 0.16 for dnDSA and also for ABMR when 
using rATG versus basiliximab (Table 3). For those patients who did develop dnDSA, 
levels were strikingly lower with rATG (mean 455 MFI versus 3,652 with basiliximab; 
p=0.02). These results suggest that rATG induction achieves a decrease in dnDSA 
production in moderately sensitized patients over the first three years following kidney 
transplantation compared to IL-2RA induction [71]. 
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A randomized prospective pilot study by Ejaz et al has compared rates of dnDSA 
between kidney transplant patients receiving rATG alone, or with the addition of 
rituximab, bortezomib or both rituximab and bortezomib (the number of rATG doses was 
reduced according to the concomitant therapy) [62]. The study population was at high 
risk, selected on the basis of PRA ≥20% (or historical PRA ≥50%), T-cell or B-cell 
positive crossmatch on flow cytometry, or positive CDC crossmatch with confirmed DSA, 
or loss of a previous graft to acute rejection. Maintenance immunosuppression 
comprised tacrolimus, MMF and steroids. At the end of the one-year study, there was no 
difference in the rates of dnDSA or ABMR between the four groups, although absolute 
numbers were low (Table 3). Based on these initial data, addition of profound naïve and 
memory B-cell depletion using rituximab, or plasma cell apoptosis via bortezomib, do not 
appear to further inhibit dnDSA production in sensitized kidney transplant patients given 
rATG induction, although further data are required. In another comparative analysis, 
Todeschini and colleagues undertook a retrospective study in which they compared 
lymphocyte reconstitution and dnDSA in 16 kidney transplant patients treated with 
alemtuzumab induction versus a matched cohort of 32 rATG-treated patients [72]. All 
patients were DSA-negative at time of transplant, but by year 1 the incidence of dnDSA 
was significantly lower in the rATG cohort (12.5% versus 50%, p=0.01), a difference the 
authors attributed to alemtuzumab-induced changes to B-cell phenotypes, notably an 
expansion of naïve B-cells [72].  
Conclusions 
 
There is currently intense interest in the prognostic importance of preformed DSA and 
newly formed DSA after organ transplantation, but undertaking trials to define the best 
immunosuppressive strategy to minimize the risks associated with DSA is challenging. 
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Controlled trials of desensitization techniques are limited by ethical considerations for a 
control arm and lack of agreement on suitable endpoints such as DSA titers or 
histological changes. Evaluation of prevention of dnDSA is less problematic, but is likely 
to be restricted to patients with at least moderate sensitization to avoid unnecessary 
intervention. Comparative studies of immunosuppressive agents are now starting to 
routinely include baseline assessments of anti-HLA DSA status, and to monitor DSA 
post-transplant, but in the meantime the transplant community is required to make 
prescribing decisions based on the available, imperfect evidence base.  
Despite these caveats, rATG appears to inhibit DSA production. rATG induction may be 
helpful in reducing the risk of ABMR in presensitized kidney transplant patients with 
high-strength DSA. In patients with low-strength preformed DSA, regimens including 
rATG induction have been effective in avoiding ABMR and achieving good graft survival 
rates. However, comparative data are lacking which makes it difficult to draw 
conclusions. Consistent with results from randomized trials showing improved BPAR 
rates with rATG versus IL-2RA induction [13,14] in high immunological risk kidney 
transplant recipients and, in one trial, improved graft survival versus no induction [15], 
rATG induction appears to reduce the risk of dnDSA and ABMR in moderately sensitized 
patients compared to non-B-cell depleting IL2-RA induction therapy [71].  
Future studies of rATG could usefully include a protocol-defined schedule for DSA 
monitoring to monitor DSA recurrence after desensitization and occurrence of de novo 
DSA, with longer-term follow-up.  
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Figure legend 
 
Figure 1. (a) De novo donor specific antibodies [dnDSA] and (b) antibody-mediated 
rejection [ABMR] during the first three years after kidney transplantation in 114 
moderately sensitized patients in an observational study (Kaplan-Meier estimates).  
Adapted with permission from Reference 71 
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Table 1. rATG induction in patients receiving desensitizing regimens prior to kidney transplantation 
 
Study Design/ donor 
type 
n Crossmatch detection 
method 
Sub-
groups 
Desensitization  Induction/ 
maintenance 
immuno-
suppression 
Follow-
up 
AMBR Graft 
survival  
Patient 
survival 
Low-strength DSA 
Knight 2013 
[51] 
Retrospective 
Living donor 
44 CDC + 
flow cytometry 
CDC XM-
negative FC 
XM-
negative 
None rATG 
TAC 
MMF 
Steroids 
Median 
26 
months 
3.3% 100% - 
CDC XM-
negative 
FC XM-
positive 
0% 100% - 
Bächler 
2010 [49] 
Prospective  
Historical 
controls  
Deceased or 
living donor 
37 
(+ 67 
controls) 
CDC + SAFB Prospective 
cohort, 
SAFB XM-
positive 
IViG rATG 
TAC 
MMF 
Steroids 
Median 2 
years 
11% at 
month 6 
0% due to 
ABMR at 
year 1 
- 
Controls, 
SAFB XM-
positive 
None No rATG 
Various 
Median 
8.5 years 
46% at 
month 6 
(p=0.0002) 
7.5% due to 
ABMR at 
year 1 
Roberti 
2007 [52] 
Retrospective 
Pediatric 
patients 
Living donor 
50 CDC, flow 
cytometry, SAFB 
CDC XM-
negative 
FC XM-
negative 
SAFB XM-
negative 
None rATG 
TAC 
MMF 
Steroid 
3 years 0% 100% 96.7% 
CDC XM-
negative 
FC XM-
negative 
SAFB XM-
positive 
Basiliximab 
TAC 
MMF 
Steroids 
3 years 0% 100% 91% 
Thielke 
2005 [50] 
Retrospective 
Living donors 
16 CDC + flow 
cytometry 
- PP 
IVIg 
rATG 
TAC 
MMF 
Steroids 
 25% 100% 100% 
High DSA 
Zhang 2011 
[53] 
Retrospective 
Living donor 
14 CDC, flow 
cytometry, SAFB 
- PP 
IVIG 
±rituximab 
rATG 
TAC 
MMF 
Steroids 
1 year 14.3% 92.9% 100% 
Vo 2006 
[54] 
Retrospective 
2 subgroups (by 
induction type) 
97 CDC rATG 
induction 
IVIG TAC 
MMF 
Steroids 
2 years 21
a
 90
a
 100
a
 
Daclizumab 22
a
 84
a
 96
a
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Deceased or 
living donor 
induction 
Stegall 
2006 [55] 
3 subgroups (by 
treatment) 
 
61 CDC, flow 
cytometry, 
single- antigen 
flow beads 
Sequential 
desensitizin
g 
protocols 
PP 
Low-dose IVIG 
Rituximab 
±splenectomy 
rATG 
TAC 
MMF 
Steroids 
n/a 37% - - 
High-dose IVIG 80% - - 
PP 
Low-dose IVIG 
Rituximab 
Pre-tx rATG (5 days) 
+ Post-tx DSA 
monitoring 
29% - - 
Various DSA levels 
Mai 2009 
[56] 
Retrospective 
3 subgroups (by 
PRA) 
Deceased or 
living donor 
94 Flow cytometry PRA<20%, 
FC-XM 
negative 
none rATG 
TAC 
MMF 
Steroids 
3 years 1.7 78.6% 90.6% 
PRA >20%, 
FC XM- 
negative 
none 6.3 80.4% 93.8% 
PRA >20%, 
FC XM- 
positive 
IVIG 30.0 88.7% 93.8% 
Akalin 2008 
[57] 
Prospective 
3 subgroups (by 
DSA) 
Living donors 
35 CDC T-cell –
negative and  
CDC B-cell-
positive  
or FC-positive 
Low/moder
ate DSA 
IVIG rATG 
TAC 
MMF 
Steroids 
Median 
18  
0% 100 100% 
High DSA  IVIG 44%  78 100% 
High DSA IVIG + PP 7%  86 93% 
CDC, complement-dependent cytotoxicity; DSA, donor-specific human leukocyte antibodies; FC, flow cytometry; n/a, not available; IVIG, 
intravenous immunoglobulin; MMF, mycophenolate mofetil; PP, plasmapheresis; rATG, rabbit antithymocyte globulin; SAFB, single-antigen flow 
beads; PRA, panel reactive antibodies; TAC, tacrolimus; XM, crossmatch 
a
 Fewer primary transplants (p<0.002) and fewer patients achieving negative crossmatch (p<0.03) by time of transplant in the rATG group versus 
the daclizumab group 
Low-strength DSA defined as negative CDC crossmatch with DSA detectable by flow cytometry or single-antigen flow beads. High-strength DSA 
defined as positive CDC T-cell or B-cell crossmatch 
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Table 2. rATG induction therapy in patients with or without dnDSA  
Study Study type/ 
Time period / 
Donor type 
n Crossmatch 
detection 
method 
Induction/ 
maintenance 
immuno-
suppression 
Follow-
up 
Induction 
type 
% rATG in 
DSA+ 
patients 
% rATG in 
DSA- 
patients 
P value 
Huang 2012 
[12] 
Retrospective  
2010-2011 
Kidney or 
kidney-pancreas 
173 FC, mixed 
antigen flow 
beads + SAFB 
CsA or TAC 
MMF 
Steroids 
480 days rATG
a
 80 67 0.30 
BAS
a
 0 12 
No 
induction
a
 
20 21 
Kanter 
Berga 2011 
[33] 
Retrospective 
1997-2009 
Deceased-donor 
kidney 
321 CDC, SAFB CsA or TAC 
(otherwise not 
specified) 
Mean 62 
months 
rATG or 
BAS 
22.2 54.5
b
 0.02 
No induction 
Cooper 
2011 [8] 
Retrospective 
2007-2009 
Kidney or 
kidney-pancreas 
244 FC + mixed 
antigen flow 
beads 
TAC
a
 
MMF
a
 
Steroids
a
 
 
2 years 
rATG 66 66 0.73 
BAS 6 4 
No induction 28 30 
Hourmant 
2005 [4] 
Retrospective 
1972-2002 
Kidney or 
kidney-pancreas 
1229 ELISA, CDC 
and/or SAFB  
Mixed 5 years rATG 72
b
 58 <0.001
c
 
a
 87% of patients received TAC/MMF/steroids 
b
 70% in patients with non-donor specific HLA antibodies 
c
 78% in patients with non-donor specific HLA antibodies 
d
 Significance was lost on multivariate analysis 
BAS, basiliximab; CDC, complement-dependent cytotoxicity; CsA, cyclosporine; DSA, donor-specific human leukocyte antibodies; FC, flow 
cytometry; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; SAFB, single-antigen flow beads; TAC, tacrolimus 
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Table 3. dnDSA production in rATG-treated transplant patients 
 
 
Study Study type/ 
Time period / 
Donor type 
n Crossmatch 
detection 
method 
Induction/ 
maintenance 
immuno-
suppression 
Follow-
up 
Induction 
type 
% dnDSA at last 
follow-up 
% ABMR at last 
follow-up 
Brokhof 
2014 [71] 
Observational 
2009-2011 
Deceased-
donor kidney 
114 SAFB TAC 
MMF 
Steroids 
3 years rATG HR 0.16, 95% CI 
0.04-1.50, p=0.003 
for rATG vs BAS
a
 
HR 0.16, 95% CI 
0.05-0.60, 
p=0.006 for rATG 
vs BAS
a
 
BAS 
Ejaz 2013 
[62] 
Prospective 
Randomized 
2008-2013 
Kidney 
40 CDC, FC, 
SAFB 
TAC 
MMF 
Steroids 
1 year rATG 30% p=0.70 10% p=0.36 
rATG + 
rituximab 
30% 0% 
rATG + 
bortezomib 
10% 30% 
rATG + 
rituximab + 
bortezomib 
30% 10% 
Todeschini 
2013 [72] 
Retrospective 
Matched 
cohort 
Kidney 
48 Mixed antigen 
flow beads 
Low-dose 
sirolimus or 
low-dose CsA 
MMF 
Steroids to day 
7 
 
2 years Low-dose 
rATG + 
BAS 
12.5% p=0.011 - 
Alemtuz-
umab 
50% - 
Delgado 
2009 [70] 
Prospective 
First kidney 
transplant 
37 CDC, mixed 
antigen flow 
beads + SAFB 
TAC 
MMF 
± Steroids 
≤5 years rATG + 
steroids 
6.3% - 
rATG no 
steroids 
0% - 
ABMR, antibody-mediated rejection; BAS, basiliximab; CDC, complement-dependent cytotoxicity; CI, confidence interval; CsA, cyclosporine; 
dnDSA, de novo donor-specific human leukocyte antibodies; FC, flow cytometry; n/a, not available; HR, hazard ratio; MMF, mycophenolate 
mofetil; rATG, rabbit antithymocyte globulin; SAFB, single-antigen flow beads; TAC, tacrolimus 
a
 Multivariate analysis  
 
